Kelly Financial Services LLC Astrazeneca PLC Transaction History

Kelly Financial Services LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Jul 17, 2024	BUY	$61.03 - $69.57 $61 - $69	1 Added 2.78%	37 $2,000
Q1 2023 Jul 17, 2024	SELL	$63.15 - $71.6 $1,957 - $2,219	-31 Reduced 46.27%	36 $2.51 Million
Q3 2022 Jul 17, 2024	SELL	$53.02 - $135.75 $1,060 - $2,715	-20 Reduced 22.99%	67 $3.67 Million
Q1 2022 Jul 17, 2024	BUY	$55.72 - $67.12 $55 - $67	1 Added 1.16%	87 $5.76 Million
Q4 2021 Jul 17, 2024	BUY	$54.02 - $63.83 $2,755 - $3,255	51 Added 145.71%	86 $5.04 Million
Q3 2021 Jul 17, 2024	SELL	$55.56 - $60.79 $115,675 - $126,564	-2,082 Reduced 98.35%	35 $2.13 Million
Q2 2021 Jul 17, 2024	BUY	$48.42 - $60.18 $100,810 - $125,294	2,082 Added 5948.57%	2,117 $35,000
Q1 2021 Jul 17, 2024	SELL	$47.16 - $54.44 $2,829 - $3,266	-60 Reduced 63.16%	35 $1.76 Million
Q4 2020 Jul 17, 2024	SELL	$48.52 - $58.02 $4,269 - $5,105	-88 Reduced 48.09%	95 $4.75 Million
Q3 2020 Jul 17, 2024	BUY	$53.07 - $61.1 $1,857 - $2,138	35 Added 23.65%	183 $10 Million
Q2 2020 Jul 17, 2024	BUY	$43.1 - $55.31 $2,586 - $3,318	60 Added 68.18%	148 $7.83 Million
Q3 2019 Jul 17, 2024	BUY	$40.12 - $45.47 $3,530 - $4,001	88 New	88 $3.92 Million

1,361

475M

5.39M

3.75M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $203B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of Kelly Financial Services LLC, based on Form 13F filings with the SEC.

Stay updated on Kelly Financial Services LLC with notifications on news.